Activity of gemcitabine in patients with advanced pancreatic carcinoma: A review

In early phase II trials in advanced pancreatic cancer, gemcitabine demonstrated modest antitumor activity. The investigators in these studies reported that gemcitabine should be studied further in view of the degree and frequency of symptomatic improvement observed, the durability of some of the remissions, and the favorable toxicity profile.

[1]  A. Harris,et al.  Phase II study of gemcitabine in patients with advanced pancreatic cancer. , 1996, British Journal of Cancer.

[2]  E. Van Cutsem,et al.  Pancreatic cancer: a plea for more trials. , 1995, European journal of cancer.

[3]  I. Taylor.  Should further studies of chemotherapy be carried out in pancreatic cancer? , 1993, European journal of cancer.

[4]  E. Casper.  Pancreatic cancer: how can we progress? , 1993, European journal of cancer.

[5]  L. Hertel,et al.  Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.

[6]  Clifford Hudis,et al.  A phase III comparison trial of streptozotocin, mitomycin, and 5‐fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma , 1991, Cancer.

[7]  J. Wils.  Chemotherapy in pancreatic cancer: a rational pursuit? , 1991, Anti-cancer drugs.

[8]  L. Hertel,et al.  Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). , 1990, Cancer research.

[9]  W. Gregory,et al.  Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. , 1990, BMJ.

[10]  J. Krook,et al.  A phase III trial on the therapy of advanced pancreatic carcinoma evaluations of the mallinson regimen and combined 5‐fluorouracil, doxorubicin, and cisplatin , 1990, Cancer.

[11]  L. Panasci,et al.  Chemotherapy for advanced pancreatic cancer. A comparison of 5‐fluorouracil, adriamycin, and mitomycin (fam) with 5‐fluorouracil, streptozotocin, and mitomycin (fsm) , 1986, Cancer.

[12]  T. Fleming,et al.  A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. , 1985, JAMA.

[13]  S. Balcerzak,et al.  Randomized trial of 5‐fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest oncology group study , 1983, Cancer.

[14]  G. Higgins,et al.  Randomized study of 5‐FU and ccnu in pancreatic cancer: Report of the veterans administration surgical adjuvant cancer chemotherapy study group , 1981, Cancer.